Literature DB >> 12738778

The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor.

Michael D Oberst1, Cicely A Williams, Robert B Dickson, Michael D Johnson, Chen-Yong Lin.   

Abstract

The activation of matriptase requires proteolytic cleavage at a canonical activation motif that converts the enzyme from a one-chain zymogen to an active, two-chain protease. In this study, matriptase bearing a mutation in its catalytic triad was unable to undergo this activational cleavage, suggesting that the activating cleavage occurs via a transactivation mechanism where interaction between matriptase zymogen molecules leads to activation of the protease. Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains. Its cognate inhibitor, hepatocyte growth factor activator inhibitor-1, may also participate in the activation of matriptase, based on the observation that matriptase activation did not occur when the protease was co-expressed with hepatocyte growth factor activator inhibitor-1 mutated in its low density lipoprotein receptor class A domain. These results suggest that besides matriptase catalytic activity, matriptase activation requires post-translational modification of the protease, intact noncatalytic domains, and its cognate inhibitor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738778     DOI: 10.1074/jbc.M304282200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

1.  Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade.

Authors:  Zhenghong Xu; Ya-Wen Chen; Aruna Battu; Paul Wilder; David Weber; Wenbo Yu; Alexander D Mackerell; Li-Mei Chen; Karl X Chai; Michael D Johnson; Chen-Yong Lin
Journal:  J Med Chem       Date:  2011-10-12       Impact factor: 7.446

Review 2.  The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment.

Authors:  Toni M Antalis; Marguerite S Buzza; Kathryn M Hodge; John D Hooper; Sarah Netzel-Arnett
Journal:  Biochem J       Date:  2010-06-15       Impact factor: 3.857

3.  Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta.

Authors:  Hiroyuki Tanaka; Koki Nagaike; Naoki Takeda; Hiroshi Itoh; Kazuyo Kohama; Tsuyoshi Fukushima; Shiro Miyata; Shuichiro Uchiyama; Shunro Uchinokura; Takeshi Shimomura; Keiji Miyazawa; Naomi Kitamura; Gen Yamada; Hiroaki Kataoka
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

4.  Matriptase is involved in ErbB-2-induced prostate cancer cell invasion.

Authors:  Shang-Ru Wu; Tai-Shan Cheng; Wen-Chi Chen; Hsin-Yi Shyu; Chun-Jung Ko; Hsiang-Po Huang; Chen-Hsin Teng; Chia-Hau Lin; Michael D Johnson; Chen-Yong Lin; Ming-Shyue Lee
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

5.  HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase.

Authors:  C-H Tsai; C-H Teng; Y-T Tu; T-S Cheng; S-R Wu; C-J Ko; H-Y Shyu; S-W Lan; H-P Huang; S-F Tzeng; M D Johnson; C-Y Lin; P-W Hsiao; M-S Lee
Journal:  Oncogene       Date:  2013-10-14       Impact factor: 9.867

6.  Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase.

Authors:  Lina Basel-Vanagaite; Revital Attia; Akemi Ishida-Yamamoto; Limor Rainshtein; Dan Ben Amitai; Raziel Lurie; Metsada Pasmanik-Chor; Margarita Indelman; Alex Zvulunov; Shirley Saban; Nurit Magal; Eli Sprecher; Mordechai Shohat
Journal:  Am J Hum Genet       Date:  2007-01-23       Impact factor: 11.025

7.  Requirement of the activity of hepatocyte growth factor activator inhibitor type 1 for the extracellular appearance of a transmembrane serine protease matriptase in monkey kidney COS-1 cells.

Authors:  Yuka Miyake; Satoshi Tsuzuki; Makoto Yasumoto; Tohru Fushiki; Kuniyo Inouye
Journal:  Cytotechnology       Date:  2009-08-05       Impact factor: 2.058

8.  Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition.

Authors:  Jehng-Kang Wang; Ming-Shyue Lee; I-Chu Tseng; Feng-Pai Chou; Ya-Wen Chen; Amy Fulton; Herng-Sheng Lee; Cheng-Jueng Chen; Michael D Johnson; Chen-Yong Lin
Journal:  Am J Physiol Cell Physiol       Date:  2009-06-17       Impact factor: 4.249

9.  Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity.

Authors:  Wei Wang; Xudong Liao; Koichi Fukuda; Sabine Knappe; Faye Wu; Daniel L Dries; Jun Qin; Qingyu Wu
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

10.  Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis.

Authors:  Joanna Selzer-Plon; Jette Bornholdt; Stine Friis; Hanne C Bisgaard; Inger Mb Lothe; Kjell M Tveit; Elin H Kure; Ulla Vogel; Lotte K Vogel
Journal:  BMC Cancer       Date:  2009-06-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.